20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Generate Biomedicines, Inc. Common Stock (GENB) operates in the BIOTECHNOLOGY industry and is headquartered in Somerville, United States with about 312 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, GENB reported $32M in revenue and ($203M) in net income.
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Interactive charts & full statements → Open the GENB valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | $32M | $32M | $20M |
| Operating Income (EBIT) | ($244M) | ($235M) | ($197M) |
| Operating Margin % | -751.2% | -737.0% | -962.6% |
| Net Income | ($223M) | ($203M) | ($174M) |
| Net Margin % | -685.9% | -637.0% | -849.4% |
| EBITDA | — | ($208M) | ($164M) |
| Earnings Per Share (EPS) | — | $-4.06 | $-1.36 |
| Shares Outstanding (M) | 128M | 50M | 127M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total Revenue | $6M | $7M | $10M | $9M |
| Operating Income (EBIT) | ($72M) | ($64M) | ($60M) | ($48M) |
| Operating Margin % | -1134.2% | -887.5% | -593.8% | -546.1% |
| Net Income | ($67M) | ($61M) | ($52M) | ($42M) |
| Net Margin % | -1065.2% | -850.6% | -517.6% | -472.7% |
| EBITDA | ($64M) | ($61M) | — | — |
| Earnings Per Share (EPS) | $-0.52 | $-0.48 | — | — |
| Shares Outstanding (M) | 128M | 128M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($240M) | ($201M) | ($118M) |
| Capital Expenditures (CapEx) | $6M | $4M | $3M |
| Free Cash Flow (FCF) | ($246M) | ($204M) | ($121M) |
| FCF Margin % | -756.9% | -640.1% | -592.4% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($58M) | ($80M) | ($49M) | ($53M) |
| Capital Expenditures (CapEx) | $1M | $4M | $0M | $1M |
| Free Cash Flow (FCF) | ($59M) | ($84M) | ($49M) | ($54M) |
| FCF Margin % | -932.5% | -1165.1% | -482.8% | -611.6% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets | $562M | $330M | $518M |
| Cash & Cash Equivalents | $135M | $122M | $176M |
| Total Liabilities | $106M | $953M | $953M |
| Total Debt (Short + Long-Term) | $14M | $15M | $17M |
| Total Shareholders' Equity | $456M | ($616M) | ($435M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GENB viewer.
About TickerBase · Data methodology & sources · Privacy · Terms